Side-by-side · Research reference

5-Amino-1MQvsLivagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongAUTO-DRAFTED8/38 cited

BAnimal-StrongHUMAN-REVIEWED20/32 cited

5-Amino-1MQ

NNMT inhibitor · Methylation / SAM modulation

100–200 mgDaily dose (oral)Neelakantan 2018

AnimalEvidence levelNeelakantan 2018

HoursHalf-life (est)

Oral · Once daily fasted

Livagen

Khavinson Bioregulator · Hepatoprotective Tetrapeptide

50%Dipeptidase inhibitionTimofeeva 2005

Oral / SQRoutes tested

LiverTarget tissueKhavinson 2001

Oral or SQ · Tissue-specific to liver

01Mechanism of Action

Parameter

5-Amino-1MQ

Livagen

Primary target

Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018

Hepatocyte protein synthesis machineryBrodskiĭ 2001

Pathway

NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018

Tissue-specific bioregulator → Hepatocyte stimulation → Protein synthesis normalizationBrodskiĭ 2001 Khavinson 2001

Downstream effect

Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018

Age-dependent enzyme normalization, hepatoprotection in fibrosis/hepatitis models, elevated protein synthesis in senescent hepatocytes

Feedback intact?

—

Origin

Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018

Directed chemical synthesis from amino acid analysis of liver polypeptide preparations (Ventvil)

Antibody development

—

02Dosage Protocols

Parameter

5-Amino-1MQ

Livagen

Standard dose

100–200 mg / day oralNeelakantan 2018

Anecdotal community range; murine doses scaled.

—

Frequency

Once daily, fasted

—

Lower / starter dose

50 mg / day

—

Evidence basis

Animal-strong; no human RCT dataNeelakantan 2018

Animal models (rats, 1–24 months age); in vitro hepatocyte cultureTimofeeva 2005 Brodskiĭ 2001 Khavinson 2002

Duration

8–12 weeks per cycle

—

Form

Oral capsule

—

Timing

Morning fasted preferred

—

Half-life

Hours (estimated; no human PK published)

—

Animal dose (oral)

—

Not specified in abstracts; 2-week administration protocolTimofeeva 2005

Per os administration in rats.

Duration (experimental)

—

2 weeks (enzyme study); up to 24 months (cell culture)Timofeeva 2005 Brodskiĭ 2001

Route

—

Oral or subcutaneous

Resists peptidase hydrolysis, enabling oral bioavailability.Timofeeva 2005

Human data

—

None in provided literature

04Side Effects & Safety

Parameter

5-Amino-1MQ

Livagen

GI symptoms

Mild nausea (anecdotal)

—

Methylation disruption

Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)

—

Long-term safety

Unknown — no human trials

—

Cancer risk

Unclear — NNMT also studied in oncology contexts

—

Pregnancy / OB

Avoid

—

Drug interactions

Theoretical with niacin / B-vitamin supplements

—

Reported adverse effects

—

None documented in animal studies

Human safety data

—

No human trials in provided literature

Peptide hydrolysis

—

Weakly hydrolyzed; minimal breakdown by intestinal enzymesTimofeeva 2005

Absolute Contraindications

5-Amino-1MQ

·Pregnancy / breastfeeding
·Active malignancy

Livagen

—

Relative Contraindications

5-Amino-1MQ

·Methylation-sensitive conditions (MTHFR mutation)
·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)

Livagen

—

05Administration Protocol

Parameter

5-Amino-1MQ

Livagen

1. Form

Oral capsule. No injection.

Oral administration supported by peptidase resistance. Subcutaneous route used in organotypic culture experiments.Timofeeva 2005 Khavinson 2001

2. Administration

Take with water, fasted preferred.

No specific timing documented. Two-week protocols used in animal models with daily administration.Timofeeva 2005

3. Timing

Morning fasted.

Elderly individuals may exhibit different enzyme normalization patterns than younger cohorts, based on rat age-stratified findings.Timofeeva 2005

4. Storage

Room temp ≤25 °C, dry place.

—

5. Caveat

Monitor B-vitamin status with chronic use.

—